MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

by | Apr 24, 2023

MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its novel GBS vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium.

GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide. It is normally associated with infection in pregnant women and new-born babies; however, invasive GBS disease in adults has been increasing over the last 40 years. 

Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner